REHOVOT, Israel, November 10, 2021 / PRNewswire / – Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life science product development in multiple market segments, today announced it has been informed by the Israel Authority innovation (IIA) of the IIA’s decision to fund a second 18-month period of the CRISPR-IL consortium set up last year. The consortium’s mission is to develop and validate an end-to-end artificial intelligence system – “Go-Genome“ – for genome editing in several species for applications in the pharmaceutical, agricultural and aquaculture fields.
The CRISPR-IL consortium was initially approved by the Israel Innovation Authority for a period of 18 months with a total budget of approximately ILS 40 million. This current approval, based on the consortium’s accomplishments to date, is for a second 18-month period and additional budget of approximately ILS 45 million (approx. $ 14.4 million), funded in part by a grant from The IIA. CRISPR-IL participants include leading Israeli companies, medical institutions, and academic institutions. Dr. Eyal Emmanuel, VP New Directions of Evogene, continues to chair the CRISPR-IL consortium.
The first research period was devoted to successfully developing a first version of “Go-Genome“, an end-to-end genome editing support platform, encompassing various editing datasets aimed at improving editing efficiency.”Go-Genome“then allowed the design of thousands of gRNAs, performed thousands of successful editing experiments in different cells and analyzed the data obtained. These experiments included editing hundreds of genetic targets across a variety of organisms in the fields of pharma (human) and agriculture (plants and animals).
During the second research period, the consortium aims to improve “Go-Genome’s“Learning models regarding editing efficiency with a strong emphasis on the specificity of genome editing, indicating editing exclusively on the intended target.”Go-GenomeComputer learning models of “should be trained and validated by hundreds of genome editing experiments, conducted by consortium participants. These experiments aim to produce unique data from edited living cells, which is currently not available on such scale and diversity in the public domain.
Beyond activities falling within the scope of the consortium, participating companies can use “Go-Genome“for their own product development activities. In this regard, Evogene is currently conducting various proof-of-concept experiments in plant tissues examining the feasibility of increasing the production of ingredients such as natural dyes and anti-aging agents to for food or cosmetic purposes.
Dr. Eyal Emmanuel, President of the CRISPR-IL consortium and VP New Directions of Evogene, commented: “We are delighted to continue our important research in one of the areas of cutting edge innovation – the fusion of computing power and genetics. The approval of the second consortium period by The IIA is a vote of confidence in Israeli research. community and is recognition of the importance of CRISPR-IL’s work. These accomplishments could lay the groundwork for exciting new business directions for Evogene. “
Dr. Nir Arbel, Product manager, said: “Thanks to Evogene’s work as part of the consortium, we are expanding our artificial intelligence capabilities and expanding the range of our AI generator solution, for the development of genomics-based products. by Evogene AI generator The solution already includes computational capabilities to identify ‘where’, ‘who’ and ‘how’ changes need to be made to achieve a specific trait, and capabilities being developed as part of the consortium are expected to improve and expand. more of these capabilities. ”
About the CRISPR-IL consortium:
The CRISPR-IL consortium intends to develop a system based on artificial intelligence, “Go-Genome“, providing users with improved workflows for genome editing. The system aims to provide end-to-end solutions, from the user interface to an accurate measurement tool. The system should include the computer design of the DNA modification on target, with minimal crashes, off target modifications, improve efficiency of modifications and provide an accurate measurement tool to ensure the desired modification has been made. This system is designed to be effective in several species, including human, plant and some animal DNA applicable to market segments in pharma, agriculture and aquaculture.In addition to Evogene, key participants include BTG – Bio-technology General Israel, Colors Farm, Hazera seeds, NRGene, Pluristem, Rahan Meristem Ltd., BetterSeeds, FreezeM; Sheba Medical Center, Schneider for children Medical Center; Bar-Ilan University, Ben Gurion University of the Negev, Hebrew University of Jerusalem, IDC Herzliya, Tel Aviv University and the Weizmann Institute.
About Evogene Ltée:
Evogene (NASDAQ: EVGN, TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development across multiple life science-based industries, including human health and l agriculture, through the use of its widely applicable computational predictive biology (CPB). Platform. The CPB platform, incorporating an in-depth understanding of biology harnessed through the power of big data and artificial intelligence, was designed to computer-discover and uniquely guide the development of life science-based products. on microbes, small molecules and genetic elements. Using the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapies through Biomica Ltd., medical cannabis through Canonic Ltd., agro-biological products through Lavie Bio Ltd., agrochemicals via AgPlenus Ltd., and ag-solutions for the production of castor oil via Casterra Ag Ltd. For more information, please visit: www.evogene.com.
This press release contains “forward-looking statements” relating to future events. These statements can be identified by words such as “may”, “could”, “expects”, “intends”, “plans”, “plans”, “believes”, “plans”, “believes”. Or words with similar meanings. For example, Evogene uses forward-looking statements in this press release when discussing the goals and work plans of the consortium, the expected benefits of the Go-Genome system, and the expansion of the Company’s capabilities and solutions. These statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties that are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by these forward-looking statements due to various factors, many of which are beyond the control of Evogene. and its subsidiaries, including, without limitation, the risk factors contained in Evogene’s reports filed with the relevant securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Evogene Investor Contact:
American Investor Relations:
Head of Investor Relations and Public Relations
E: [email protected]
T: + 972-8-931-1940
E: [email protected]
T: +1 646-653-7035
 GRNA – Guide RNA is a piece of RNA that serves as a guide for enzymes targeting RNA or DNA, with which they form complexes. Very often, these enzymes will delete, insert or otherwise alter the targeted RNA or DNA.
 Data is collected through experiments and then sent back to “Go-Genome“to improve its learning models